Clinical trials: Liver Transplants
Vasoplegic Syndrome, Liver Transplant; Complications
Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients
This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.
- Trial name
- NCT04054999
- Testing
- Hydroxocobalamin, Methylene Blue
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Liver Cirrhosis
Human Fetal Liver Cell Transplantation in Chronic Liver Failure
The herein study consists in the transplantation of liver progenitor cells isolated from human fetal liver tissue with the aim of improving conventional liver therapy and broadening therapeutical options other than liver…
- Trial name
- hFLCTx (NCT01013194)
- Testing
- Human Fetal Liver Cell Transplantation
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received…
- Trial name
- NCT02781571
- Testing
- SOF/VEL
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 79 people
- Sponsor
- Gilead Sciences
Liver Transplant Rejection
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
- Trial name
- CONTRAIL I (NCT03781414)
- Testing
- CFZ533, Tacrolimus - MMF - corticosteroids
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
End Stage Renal Disease, Hepatitis C
Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time.
- Trial name
- NCT04575896
- Testing
- Glecaprevir/pibrentasvir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Heart Transplantation, Liver Transplantation
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a single intravenous infusion.
- Conditions
- Heart Transplantation, Liver Transplantation, Bone Resorption
- Trial name
- CTX (NCT00297830)
- Testing
- Zoledronic acid, Alendronate
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Columbia University
Liver Transplantation
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.
This 2 arm study will compare the efficacy and safety of two CellCept-containing treatment regimens in de novo liver transplant patients.
- Trial name
- NCT00545402
- Testing
- Mycophenolate mofetil, adjusted dose, Tacrolimus, Corticosteroids, IV
- Where
- 16 sites in France
- Volunteers
- 180 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
This trial was open to participants who had received a liver transplant or had cirrhosis due to chronic HCV. All subjects were treated with daclatasvir+sofosbuvir+ribavirin and were followed for 24 weeks post treatment.
- Trial name
- ALLY 1 (NCT02032875)
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 5 sites in United States
- Volunteers
- 116 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
Hepatitis C, Cirrhosis
Intravenous Interferon During Liver Transplant
The main goal of this study is to prevent liver allograft infection with Hepatitis C virus in hepatitis C positive patients undergoing liver transplantation.
- Trial name
- NCT01192698
- Testing
- IV interferon
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Liver Failure, Carcinoma, Hepatocellular
Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study
This study will assess the feasibility of lower limb-ischemia induced Remote Ischemic Conditioning (RIC) in the perioperative period before, during, and after Orthotopic Liver Transplantation (OLT).
- Trial name
- NCT02635347
- Testing
- Remote Ischemic Conditioning (RIC), Pneumatic tourniquet
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Rutgers, The State University of New Jersey
Heart Transplantation, Liver Transplantation
Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant
The purpose of this study was to offer patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) the possibility to continue FK506E (MR4) until commercial availability of the drug and to record…
- Conditions
- Heart Transplantation, Liver Transplantation, Kidney Transplantation
- Trial name
- NCT02118896
- Testing
- FK506E
- Where
- 105 sites in United States, Australia and 21 more
- Volunteers
- 850 people
- Sponsor
- Astellas Pharma Europe Ltd.
Liver Transplantation
RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency
The purpose of the study is to assess the effect of everolimus initiation together with reduction or discontinuation of calcineurin inhibitor (CNI) on renal function in maintenance liver transplant recipients with CNI-related…
- Trial name
- NCT00267189
- Testing
- Everolimus, Calcineurin inhibitors (CNI), Mycophenolate acid (MPA)/ Azathioprine (AZA)
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 145 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplant Recipient
Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients
The reason for this extension is to evaluate the long-term safety and efficacy of two concentration-controlled everolimus regimen in de novo liver transplant recipients.
- Trial name
- NCT01150097
- Testing
- Tacrolimus (reduced tacrolimus), Everolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination)
- Where
- 57 sites in United States, Argentina and 14 more
- Volunteers
- 284 people
- Sponsor
- Novartis Pharmaceuticals
Immunosuppression
Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients
The objective of this study is to determine the tolerability and safety of Myfortic in liver transplant patients. Patients receiving CellCept who have GI side effects will have CellCept discontinued and changed to Myfortic…
- Trial name
- NCT00336895
- Testing
- Myfortic
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Pittsburgh
Liver Transplantation
Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients
Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients.
- Trial name
- NCT00405652
- Testing
- Enteric-coated Mycophenolate sodium (EC-MPS)
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Tissue Donors, Liver Transplantation
The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy
Liver transplantation is the gold standard treatment for patients with end-stage liver disease. Despite its outstanding success, liver transplantation still entails certain complications including ischemia-reperfusion injury.
- Conditions
- Tissue Donors, Liver Transplantation, Ischemia Reperfusion Injury
- Trial name
- NCT03386435
- Testing
- remote ischemic preconditioning
- Where
- South Korea
- Volunteers
- 160 people
- Sponsor
- Asan Medical Center
Liver Cirrhosis, Hepatocellular Carcinoma
Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
The objective of this study is to evaluate feasibility and safety of the adoptive transfer of activated natural killer (NK) cells extracted from cadaveric donor liver graft perfusate for liver transplant recipients with…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Evidence of Liver Transplantation
- Trial name
- MIAMINK (NCT01147380)
- Testing
- Liver NK cell inoculation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Seigo Nishida
Chronic Hepatitis B
Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant
The objective of this 96-week study was to evaluate the safety and antiviral efficacy of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, coformulated; Truvada®) with or without hepatitis B immunoglobulin (HBIg) in…
- Trial name
- NCT00507689
- Testing
- FTC/TDF, Hepatitis B Immunoglobulin (HBIg)
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
Frailty, Cirrhosis
LIFT Intervention in Liver Transplant Candidates
Frailty is a significant problem in patients undergoing liver transplant and is associated with poor outcomes and survival. Hence, optimizing physical fitness and counteracting frailty is important.
- Conditions
- Frailty, Cirrhosis, Liver Transplant
- Trial name
- NCT04836923
- Testing
- "LIver FrailTy" intervention (LIFT)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Northwestern University